These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19593194)

  • 41. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
    Lee KU; Jeon YW; Lee HK; Jun TY
    Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel approach to rater training and certification in multinational trials.
    Jeglic E; Kobak KA; Engelhardt N; Williams JB; Lipsitz JD; Salvucci D; Bryson H; Bellew K
    Int Clin Psychopharmacol; 2007 Jul; 22(4):187-91. PubMed ID: 17519640
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to make the decision to resort to an APAP)].
    Chéreau I; Gorwood P; Mouchabac S
    Encephale; 2009 Jan; Suppl 3():S97-100. PubMed ID: 19268186
    [No Abstract]   [Full Text] [Related]  

  • 44. [Treatment of schizophrenia: what the family doctor should know].
    Gruber O; Falkai P
    MMW Fortschr Med; 2008 May; 150 Suppl 2():16-9; quiz 20. PubMed ID: 18680837
    [No Abstract]   [Full Text] [Related]  

  • 45. Clinical antipsychotic trials of intervention effectiveness study: a pragmatic trial?
    Manjunatha N; Saddichha S
    J Clin Psychopharmacol; 2009 Aug; 29(4):410-1. PubMed ID: 19593195
    [No Abstract]   [Full Text] [Related]  

  • 46. Comments on "Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial" by Dr Ko and colleagues.
    Pae CU
    J Clin Psychopharmacol; 2009 Apr; 29(2):194-5; author reply 196-7. PubMed ID: 19512992
    [No Abstract]   [Full Text] [Related]  

  • 47. Should the CATIE study be a wake-up call?
    Ragins M
    Psychiatr Serv; 2005 Dec; 56(12):1489. PubMed ID: 16339608
    [No Abstract]   [Full Text] [Related]  

  • 48. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of Canadian psychiatry].
    Stip E
    Encephale; 2009 Jan; Suppl 3():S115-8. PubMed ID: 19268180
    [No Abstract]   [Full Text] [Related]  

  • 49. Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?
    Alphs L; Benedetti F; Fleischhacker WW; Kane JM
    Int J Neuropsychopharmacol; 2012 Aug; 15(7):1003-14. PubMed ID: 22217384
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Measuring remission in schizophrenia: response to Sethuraman et al., 2005.
    Kujawa M; Bossie CA; Lasser RA
    Schizophr Res; 2006 Mar; 83(1):109-10. PubMed ID: 16423505
    [No Abstract]   [Full Text] [Related]  

  • 51. Causal model of insight and psychopathology based on the PANSS factors: 1-year cross-sectional and longitudinal revalidation.
    Hwang SS; Chang JS; Lee KY; Kim SH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2009 Jul; 24(4):189-98. PubMed ID: 19521247
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Study on clozapine treatment at the Charles Perrens Hospital in Bordeaux, 15 years after its marketing].
    Mercier C; Bret P; Bret MC; Queuille E
    Encephale; 2009 Sep; 35(4):321-9. PubMed ID: 19748368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). What are the limiting factors in resort to an APAP and how to overcome them].
    Canceil O; Limosin F; Passerieux C
    Encephale; 2009 Jan; Suppl 3():S101-7. PubMed ID: 19268178
    [No Abstract]   [Full Text] [Related]  

  • 54. A carbamazepine trial in chronic, treatment-refractory schizophrenia.
    Sramek J; Herrera J; Costa J; Heh C; Tran-Johnson T; Simpson G
    Am J Psychiatry; 1988 Jun; 145(6):748-50. PubMed ID: 3285702
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical aspects of schizophrenia].
    Versaevel C
    Soins Psychiatr; 2007; (249):18-23. PubMed ID: 17438981
    [No Abstract]   [Full Text] [Related]  

  • 56. Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations.
    Paz E; Bouzas L; Hermida J; Brenlla J; Tutor JC
    Clin Biochem; 2008 May; 41(7-8):603-6. PubMed ID: 18280253
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Switching antipsychotic medications: a 2-year chart-review study exploring patient characteristics and psychiatric service use of schizophrenia patients.
    Schneider AL; Mosier KE; Tempier RP
    J Clin Psychiatry; 2009 Jun; 70(6):937-9. PubMed ID: 19573492
    [No Abstract]   [Full Text] [Related]  

  • 58. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to evaluate the quality of observations].
    Benoit M; Pon J; Zimmermann MA
    Encephale; 2009 Jan; Suppl 3():S87-90. PubMed ID: 19268184
    [No Abstract]   [Full Text] [Related]  

  • 59. Antipsychotic effects of ceruletide (caerulein) on chronic schizophrenia.
    Moroji T; Watanabe N; Aoki N; Itoh S
    Arch Gen Psychiatry; 1982 Apr; 39(4):485-6. PubMed ID: 7039550
    [No Abstract]   [Full Text] [Related]  

  • 60. [CATIE: welcome to the real world].
    Alvarez E; Bernardo M; Roca M
    Actas Esp Psiquiatr; 2006; 34(4):213-5. PubMed ID: 16823680
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.